ENLV Stock Summary and Trading Ideas (Enlivex Therapeutics Ltd. - | NASDAQ:ENLV)

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics Ltd. - trades on the NASDAQ stock market under the symbol ENLV.

As of April 19, 2024, ENLV stock price declined to $1.39 with 32,143 million shares trading.

ENLV has a beta of 2.28, meaning it tends to be more sensitive to market movements. ENLV has a correlation of 0.04 to the broad based SPY ETF.

ENLV has a market cap of $25.81 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ENLV stock traded as high as $13.95 and as low as $1.15.

ENLV has underperformed the market in the last year with a price return of -52.1% while the SPY ETF gained +21.8%. ENLV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.9% and -63.0%, respectively, while the SPY returned +4.8% and -3.0%, respectively.

ENLV support price is $1.29 and resistance is $1.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENLV stock will trade within this expected range on the day.